| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration LB Knudsen, PF Nielsen, PO Huusfeldt, NL Johansen, K Madsen, ... Journal of medicinal chemistry 43 (9), 1664-1669, 2000 | 920 | 2000 |
| The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men H Agersø, LB Jensen, B Elbrønd, P Rolan, M Zdravkovic Diabetologia 45, 195-202, 2002 | 631 | 2002 |
| Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects T Vilsbøll, H Agersø, T Krarup, JJ Holst The Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 2003 | 567 | 2003 |
| Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, J Veldhuis, ... Diabetes 51 (2), 424-429, 2002 | 368 | 2002 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ... Diabetes care 25 (8), 1398-1404, 2002 | 364 | 2002 |
| Structure− activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness K Madsen, LB Knudsen, H Agersoe, PF Nielsen, H Thøgersen, M Wilken, ... Journal of medicinal chemistry 50 (24), 6126-6132, 2007 | 280 | 2007 |
| Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide H Østergaard, JR Bjelke, L Hansen, LC Petersen, AA Pedersen, T Elm, ... Blood, The Journal of the American Society of Hematology 118 (8), 2333-2341, 2011 | 159 | 2011 |
| Stochastic differential equations in NONMEM®: implementation, application, and comparison with ordinary differential equations CW Tornøe, RV Overgaard, H Agersø, HA Nielsen, H Madsen, ... Pharmaceutical research 22, 1247-1258, 2005 | 109 | 2005 |
| Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative H Agersø, P Vicini European journal of pharmaceutical sciences 19 (2-3), 141-150, 2003 | 85 | 2003 |
| Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults O Østerberg, RM Savic, MO Karlsson, USH Simonsson, JP Nørgaard, ... The Journal of Clinical Pharmacology 46 (10), 1204-1211, 2006 | 83 | 2006 |
| The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects T Vilsbøll, H Agersø, T Lauritsen, CF Deacon, K Aaboe, S Madsbad, ... Regulatory peptides 137 (3), 168-172, 2006 | 82 | 2006 |
| Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients H Agersø, L Seiding Larsen, A Riis, U Lövgren, MO Karlsson, ... British journal of clinical pharmacology 58 (4), 352-358, 2004 | 80 | 2004 |
| Bioavailability of amoxycillin in pigs AGERSØ, FRIIS Journal of veterinary pharmacology and therapeutics 21 (1), 41-46, 1998 | 77 | 1998 |
| Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations CW Tornøe, H Agersø, EN Jonsson, H Madsen, HA Nielsen Computer Methods and Programs in Biomedicine 76 (1), 31-40, 2004 | 66 | 2004 |
| Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs A Plum, H Agersø, L Andersen Drug Metabolism and Disposition 28 (2), 155-160, 2000 | 64 | 2000 |
| Blockade of NKG2D ameliorates disease in mice with collagen‐induced arthritis: A potential pathogenic role in chronic inflammatory arthritis AK Andersson, PF Sumariwalla, FE McCann, P Amjadi, C Chang, ... Arthritis & Rheumatism 63 (9), 2617-2629, 2011 | 50 | 2011 |
| Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies TC Nichols, C Hough, H Agersø, M Ezban, D Lillicrap Journal of Thrombosis and Haemostasis 14 (5), 894-905, 2016 | 46 | 2016 |
| Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients H Agersø, DF Brophy, H Pelzer, EJ Martin, M Carr, U Hedner, M Ezban Journal of Thrombosis and Haemostasis 9 (2), 333-338, 2011 | 46 | 2011 |
| Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle‐free device, compared to … H Agersø, J Møller‐Pedersen, S Cappi, P Thomann, B Jesussek, ... The Journal of Clinical Pharmacology 42 (11), 1262-1268, 2002 | 45 | 2002 |
| Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues CW Tornøe, H Agersø, T Senderovitz, HA Nielsen, H Madsen, ... British journal of clinical pharmacology 63 (6), 648-664, 2007 | 42 | 2007 |
